Myelodysplastic Syndromes Clinical Trials

130 recruiting

Myelodysplastic Syndromes Trials at a Glance

148 actively recruiting trials for myelodysplastic syndromes are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Phase 2 with 62 trials, with the heaviest enrollment activity in Houston, Boston, and Tampa. Lead sponsors running myelodysplastic syndromes studies include Dana-Farber Cancer Institute, M.D. Anderson Cancer Center, and Masonic Cancer Center, University of Minnesota.

Browse myelodysplastic syndromes trials by phase

Treatments under study

About Myelodysplastic Syndromes Clinical Trials

Looking for clinical trials for Myelodysplastic Syndromes? There are currently 130 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelodysplastic Syndromes trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelodysplastic Syndromes clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 148 trials

Recruiting
Phase 1Phase 2

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled24 locationsNCT05320198
Recruiting
Phase 1Phase 2

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes
National Cancer Institute (NCI)160 enrolled1 locationNCT06303193
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.27 enrolled22 locationsNCT04953910
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.18 enrolled21 locationsNCT04953897
Recruiting

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Acute Myeloid LeukemiaMyelodysplastic SyndromesGermline Mutation
National Cancer Institute (NCI)510 enrolled1 locationNCT07019155
Recruiting
Phase 2Phase 3

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled71 locationsNCT04256317
Recruiting
Phase 1Phase 2

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 1Phase 2

Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

Myelodysplastic Syndromes
West Virginia University26 enrolled1 locationNCT06923488
Recruiting
Phase 2

Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
University of Manitoba75 enrolled1 locationNCT06599762
Recruiting
Phase 2

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

Myelodysplastic Syndromes
GlaxoSmithKline80 enrolled39 locationsNCT06847867
Recruiting
Phase 2

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic SyndromesMixed Phenotype Acute LeukemiaLeukemia, Myeloid, Acute
Orca Biosystems, Inc.80 enrolled5 locationsNCT07216443
Recruiting

Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
Nantes University Hospital60 enrolled1 locationNCT06439199
Recruiting
Phase 2

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center45 enrolled1 locationNCT06597734
Recruiting
Phase 2

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Acute Myeloid LeukemiaAcute LeukemiaAML+2 more
Masonic Cancer Center, University of Minnesota132 enrolled1 locationNCT07493538
Recruiting

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

Myelodysplastic Syndromes
National Cancer Institute (NCI)1,000 enrolled1 locationNCT05588154
Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myelogenous Leukemia+7 more
Wake Forest University Health Sciences2,000 enrolled1 locationNCT01890486
Recruiting
Phase 1Phase 2

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Chordia Therapeutics, Inc.225 enrolled8 locationsNCT05732103
Recruiting
Phase 1

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Acute Myeloid LeukemiaMyelodysplastic Syndromes
GluBio Therapeutics Inc.48 enrolled8 locationsNCT06146257
Recruiting
Phase 1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled18 locationsNCT06656494
Recruiting
Phase 1

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

AMLMyelodysplastic SyndromesCML+3 more
University of Alabama at Birmingham50 enrolled1 locationNCT06047886